Evidence map›Paper›PMID 35876264›Full record

ArticleJournal of diabetes science and technology2024

Development of the Extended Infusion Set and Its Mechanism of Action.

Gina Zhang, Ohad Cohen, Sarnath Chattaraj

Abstract read
In one paragraph

Article in Journal of diabetes science and technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. The Future of Automated Insulin Delivery Systems.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
    Review
  4. Article
  5. Review
  6. Automated Insulin Delivery for Type 1 Diabetes: Present and Future.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gina ZhangMedtronic Diabetes, Northridge, CA, USA.ORCID 0000-0001-8310-016X
Ohad CohenMedtronic International Trading Sàrl, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Sarnath ChattarajMedtronic Diabetes, Northridge, CA, USA.ORCID 0000-0003-0409-0886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Continuous subcutaneous insulin infusion (CSII, or insulin pump) and continuous glucose monitoring (CGM) sensors have been increasingly used and associated with improved glycemic control by people with type 1 diabetes and insulin-requiring type 2 diabetes. Commonly used infusion sets in most CSII systems are limited to a wear time of 3 days. In contradistinction, CGM sensors are currently approved for seven and more days of wear. With the motivation to provide a 7-day infusion set that matches the CGM wear time and to improve patient experience, the recently CE-marked and FDA 510k-cleared Medtronic extended infusion set (EIS) was designed.s The EIS offers enhanced new features that include use for up to 7 days, improved convenience, comfort, and better quality of life for insulin pump users.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Blood Glucose Self-MonitoringHumansInsulinQuality of LifeBlood GlucoseInsulinCSIIextended wearinsulin infusion setunexplained hyperglycemia

Identifiers

PMID35876264
PMCPMC10973872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.